Exploring drug resistance genes in Acinetobacter baumannii using metagenomic next-generation sequencing

Area of Science:

• Clinical microbiology
• Genomics
• Infectious diseases

Background:

• Antibiotic overuse is a growing concern, necessitating advanced diagnostic tools.
• Metagenomic next-generation sequencing (mNGS) offers potential for rapid, broad-spectrum antimicrobial resistance detection.
• The clinical utility of mNGS for antimicrobial resistance testing requires further validation.

Purpose of the Study:

• To evaluate the effectiveness of mNGS in detecting antimicrobial resistance in Acinetobacter baumannii.
• To compare mNGS performance against conventional culture-based methods.
• To assess the concordance of mNGS results with clinical drug resistance assessments.

Main Methods:

• Analysis of 53 clinical Acinetobacter baumannii samples using mNGS.
• Comparison of mNGS data with results from culture-based antimicrobial susceptibility testing.
• Validation against clinical judgment of drug resistance for treatment correlation.

Main Results:

• mNGS generated an average of 8.4 × 10⁷ reads per sample, identifying 61 resistance loci.
• Class-specific accuracy exceeded 80% for β-lactams, aminoglycosides, quinolones, and minocycline.
• Identified high-frequency resistance genes including cephalosporinases, oxacillinases, and efflux pumps.

Conclusions:

• mNGS demonstrates high concordance with culture-based methods and clinical evaluations.
• mNGS is a reliable tool for comprehensive resistome profiling of Acinetobacter baumannii.
• This technology holds significant promise for clinical antimicrobial resistance testing.